Израел - Енглески - Ministry of Health

astrazeneca (israel) ltd - metformin hydrochloride; saxagliptin - film coated tablets - extended release - saxagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

Малта - Енглески - Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - saxagliptin 2.5 mg - drugs used in diabetes

Малта - Енглески - Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - saxagliptin 5 mg - drugs used in diabetes

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

astrazeneca limited - metformin hydrochloride 1000mg;  ; saxagliptin 5mg (as saxagliptin hydrochloride) - modified release tablet - 5mg/1000mg - active: metformin hydrochloride 1000mg   saxagliptin 5mg (as saxagliptin hydrochloride) excipient: carmellose sodium hydrochloric acid hypromellose magnesium stearate opacode blue s-1-10619 opadry pink 85f14452 opadry white 85f18422 purified water     - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

astrazeneca limited - metformin hydrochloride 500mg;  ; saxagliptin 5mg (as saxagliptin hydrochloride) - modified release tablet - 5mg/500mg - active: metformin hydrochloride 500mg   saxagliptin 5mg (as saxagliptin hydrochloride) excipient: carmellose sodium hydrochloric acid   hypromellose magnesium stearate microcrystalline cellulose opacode blue s-1-10619 opadry butterscotch 85f17417 opadry white 85f18422 purified water     - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - dapagliflozin (unii: 1ull0qj8uc) (dapagliflozin - unii:1ull0qj8uc), saxagliptin hydrochloride (unii: z8j84yix6l) (saxagliptin anhydrous - unii:8i7io46ivq), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - qternmet xr (dapagliflozin, saxagliptin, and metformin hydrochloride) extended-release tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use qternmet xr is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. qternmet xr initiation is intended only for patients currently taking metformin. qternmet xr is contraindicated in patients with: risk summary based on animal data showing adverse renal effects, from dapagliflozin, qternmet xr is not recommended during the second and third trimesters of pregnancy. the limited available data with qternmet xr or components (dapagliflozin and saxagliptin) in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk (see data ). there are risks to the moth

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

physicians total care, inc. - saxagliptin hydrochloride (unii: z8j84yix6l) (saxagliptin - unii:9gb927lajw) - saxagliptin 5 mg - onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. [see clinical studies (14) .] onglyza should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. onglyza has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using onglyza. [see warnings and precautions (5.1) .] history of a serious hypersensitivity reaction to onglyza, such as anaphylaxis, angioedema, or exfoliative skin conditions. [see warnings and precautions (5.3) and adverse reactions (6.2) .] there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, onglyza, like other antidiabetic medications, should be used during pregnancy only if clearly

Канада - Енглески - Health Canada

astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride) - tablet - 5mg - saxagliptin (saxagliptin hydrochloride) 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

Канада - Енглески - Health Canada

astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride) - tablet - 2.5mg - saxagliptin (saxagliptin hydrochloride) 2.5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

Канада - Енглески - Health Canada

astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride); metformin hydrochloride - tablet - 2.5mg; 500mg - saxagliptin (saxagliptin hydrochloride) 2.5mg; metformin hydrochloride 500mg - biguanides